Form PTO-1449					Attorney's Docket No. 39780-1618P2C46	Application Serial No. 09/903,520		al No.		
PINFORMATION DISCLOSURE STATEMENT				URE STATEMENT	Applicant(s)	Applicant(s)				
- 193						ASHKENAZI, et al.				
ાર્લિક પ્રાથમિક પ્રાથમિક (use green sheets if necessary)				if management	Filing Date:		Group Art Unit: 1646			
f Act a					July 11, 2001 1646  S. PATENT DOCUMENTS					
diamin	or als	of State	Date	Document No.	No-	Class	Subclass	Filing Date		
Initials		No.	Jaio	Document ito.	Name	0.000	0000000	(if appropr		
10/W 1.		8/21/90	4,950,647	Pobine et al.			10/4/88			
1		2.	7/15/97	5,648,376	Strobel et al. OCT 3 0 2005			1/19/95		
		3.	9/1/98	5,801,193	Ojo-Amaize et al.  Haskill et al.			4/15/97		
		4.	10/6/98	5,817,306	Haskill et al.			6/7/95		
V	/	5.	09/28/99	5,958,403	Storm, et al.					
7				FC	REIGN PATENT DOCUMENTS					
Examine		Ref.	Date	Document No.	Name	Class	Subclass	Transla		
Initials	_	No.		<u> </u>				YES	NO	
	_						<u> </u>	ļ		
			·		OTHER ROOMMENTS		<u> </u>	<u></u>	<u> </u>	
				/including	OTHER DOCUMENTS					
Examine	or T	Ref.	Title	(including	author, title, date, pertinent pages, etc.)	· · · · · ·				
Initials		No.	11110				•			
			Abolhassa	ni, M., "Antibacterial el	fect of borage (Echium amoenum) on Sta	phylococc	us aureus," Br	azilian Journ	al of	
6. Infectious Diseases 8:382-385 (2004).										
	7. Amirghofran, Z. et al., "Echium amoenum stimulate of lymphocyte proliferation and inhibit fo humoral antibody synthesis," Irn. J. Med. Sci. 25:119-124 (2000).									
		8.	Chapoval, A. I. et al., "Combination chemotherapy and IL-15 administration induces permanent tumor regression in a							
mouse lung tumor model: NN and 1 cell-mediated effects antagonized by 5 cells, 3. Immunor. 101.0377-0304 (133										
į į	Versus-Host Reaction and Allogeneic Skin Graft Rejection", <i>Transplantation</i> , 60:362-368 (1995).									
		40	Gennari, R. et al., "Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived							
	$\perp$	10.	sepsis by improving gut barrier function and modulating bacterial clearance," Annals of Surgery 220:68-76 (1994).							
11. Grabstein, K.H. et al., "Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 rece Science 264:965-968 (1994)				eptor,"						
	12. Kasaian, M.T. et al., "IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity," <i>Immunity</i> 16:559-569 (2002).				f the					
13. Kirchner, G.I. et al., "Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinom following subcutaneous application," <i>Br. J. Clin. Pharmacol.</i> 46:5-10 (1998).				arcinoma na	tients					
Ma, H-L et al., "IL-21 activates both innate and adaptive immunity to generate potent antitumor response.				ntitumor resp	onses that re	equire				
perforin but are independent of INF-γ," J. Immunol. <u>171</u> :508-615 (2003).										
	Naito, K. et al., "Macrophage factors which enhance the mixed leukocyte reaction initiated by dendritic cells," <i>J. Immunol.</i> 142:1834-1839 (1989).									
	Nastala, C.L. et al., "Recombinant IL-12 administration induces tumor regression in association with IFN-γ production,"				ction,"					
				Annel						
		17.	7. Pahwa, R. et al. "Recombinant interleukin 2 therapy in severe combined immunodeficiency disease," <i>Proc. Natl. Acad. Sci. USA</i> 86:5069-5073 (1989).							
6	V	18.	Patterson, 5094 (2005		iant NKT cells are required for effective in	n vitro allor	esponses," <i>J.</i>	lmmunol. <u>17:</u>	5:5087-	
				<u></u>						

П	EXAMINER:	DATE CONSIDERED:				
	[ ] Wim/h	1/17/07				
Н	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in					
Н	conformance and not considered. Include a copy of this form with next communication to applicant.					
Н	"If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the					
Н	PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).					
L	SV 2242374 v1					

		Form PTO-1449	Attorney's Docket No. 39780-1618P2C46	Application Serial No. 09/903,520		
INFOR	RMATIO	N DISCLOSURE STATEMENT	Applicant(s)			
			ASHKENAZI, et al.			
	use sev	eral sheets if necessary)	Filing Date: July 11, 2001	Group Art Unit: 1646		
Reddy, M.M. et al., "Interleukin 2 au deficiency syndrome," <i>Infect. Immu</i>						
	20.	antoli, D. et al., "Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed rmphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules," <i>J. Immunol.</i> 137:400-407 1986).				
	21.	Shim, et al., "Immunosuppressive Effects of Tautomycetin <i>in vivo</i> and <i>in vitro</i> via T cell-specific Apoptosis Induction," <i>Proc. Natl. Acad. Sci.</i> , USA, 99(16):10617-10622 (2002).				
	22.	Tarr, P.E. et al., "Granulocyte-macrophage colony-stimulating factor and the immune system," <i>Med Oncol.</i> 13:133-140 (1996).				
galactosylceramide," J. Immunol. 163			on of experimental tumor metastasis by der :2387-2391 (1999).	·		
V	24.	Tsavaris, N. et al., "Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes," Br. J. Cancer 87:21-27 (2002).				
			<del></del>			
		445-4				
_			<u> </u>			
			·.			
		· · · · · · · · · · · · · · · · · · ·				
<u></u>						

EXAMINER:	DATE CONSIDERED:			
I will	17/2/07			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				
conformance and not considered. Include a copy of this form with next communication to applicant.				

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2242374 v1